Ordinary Adjustment | Solactive Pharma Breakthrough Value Index | Effective Date 24th March 2025
Solactive Pharma Breakthrough Value Index:
In the ordinary adjustment, the following composition will be implemented effective open 24th March 2025:
| ALNYLAM PHARMACEUTICALS INC |
| AMGEN INC |
| ASTRAZENECA PLC-SPONS ADR |
| BEIGENE LTD-ADR |
| BIOCRYST PHARMACEUTICALS INC |
| BIOGEN INC |
| BIOMARIN PHARMACEUTICAL INC |
| BRISTOL-MYERS SQUIBB CO |
| CATALYST PHARMACEUTICALS INC |
| CHUGAI PHARMACEUTICAL CO LTD ORD |
| EISAI |
| GENMAB A/S |
| HALOZYME THERAPEUTICS INC |
| INCYTE CORP |
| INNOCARE PHARMA LTD |
| IONIS PHARMACEUTICALS INC |
| IPSEN SA |
| JAZZ PHARMACEUTICALS PLC |
| JOHNSON & JOHNSON |
| KYOWA KIRIN CO LTD |
| LG CHEM LTD |
| LIGAND PHARMACEUTICALS INC |
| MITSUBISHI CHEMICAL GROUP |
| NIPPON SHINYAKU CO LTD |
| NOVARTIS AG-SPONSORED ADR |
| PHARMA MAR SA |
| PHARMING GROUP NV |
| PTC THERAPEUTICS INC |
| ROYALTY PHARMA PLC- CL A |
| SAREPTA THERAPEUTICS INC |
| SWEDISH ORPHAN BIOVITRUM AB |
| TRAVERE THERAPEUTICS INC |
| ULTRAGENYX PHARMACEUTICAL INC |
| UNITED THERAPEUTICS CORP |
| VERTEX PHARMACEUTICALS INC |
| XERIS BIOPHARMA HOLDINGS INC |
| ZEVRA THERAPEUTICS INC |